Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are currently a shareholder in Galenica AG (VTX:GALE), or considering investing in ...
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Galenica AG (VTX:GALE) share price ...
Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Press release Ad hoc announcement pursuant to Art. 53 LR The Galenica ...
AstraZeneca’s ZS-9 setback last month did Relypsa a favor: It handed Veltassa sole control of the hyperkalemia market, at least for now. That couldn’t have hurt Relypsa’s chances to sell itself at a ...
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth ...
Galenica Group today announced that it has completed its previously announced acquisition of Relypsa, Inc., (RLYP). The combination of Galenica`s Vifor Pharma business unit with Relypsa will create a ...
July 21 (Reuters) - Galenica has agreed to buy Relypsa (Xetra: 0RY.DE - news) for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of ...
The healthcare group Galenica is continuing on its growth path. After continuing to grow in the first six months of 2025, the company raised its operating profit forecast on Thursday thanks to one-off ...
We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. The last dividend was quite easily covered by Galenica's earnings. This indicates that a lot of the ...
Moroccan pharmaceutical company Galenica has made its first shipment of medicines to Russia in partnership with Asia Pharm ...
(Reuters) - Galenica has agreed to buy Relypsa for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of splitting up the Swiss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results